Gene Editing Therapies for Hereditary Diseases

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell and Gene Therapy".

Deadline for manuscript submissions: closed (25 March 2026) | Viewed by 774

Special Issue Editor


E-Mail Website
Guest Editor
1. Département de Médecine Moléculaire, Université Laval, Québec, QC G1V 0A6, Canada
2. Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, QC G1E 6W2, Canada
Interests: duchenne muscular dystrophy; friedreich ataxia; alzheimer’s disease; CRISPR; base editing; myoblast transplantation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The development of genome editing technologies has improved the prospect of treatments for several hereditary diseases. For most of them, high-precision DNA correction will be feasible. Indeed, techniques such as base editing permit us to correct the four most common single-base substitutions, while prime editing can install any substitutions, insertions, and/or deletions of dozens of base pairs. Nuclease-dependent editing approaches involving double-strand DNA breaks (DSBs) often result in a high percentage of uncontrolled editing outcomes, frequently a mixture of insertions and/or deletions (indels), large deletions, and sometimes chromosomal rearrangements. Base editing and prime editing techniques have higher rates of efficiency with fewer byproducts, even in slowly dividing or non-dividing cells, which are most of the cells in adult animals. Viral and non-viral in vivo delivery methods have now been used to deliver the components of base editors and prime editors in numerous animal models. Thus, these techniques are effective agents for in vivo therapeutic genome editing, not only in animal models but also in humans. I am thus proposing the publication of a Special Issue of Cells to present the fantastic progress in these technologies and their rapid use for the development of genetically improved plants and real personalized medical treatments.

Yours faithfully,

Prof. Dr. Jacques P. Tremblay
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gene therapy
  • base editing
  • prime editing
  • genome editing
  • hereditary diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 16352 KB  
Article
Successful In Vitro Modification of the Dmd Gene Using Prime Editing
by Ayesha Siddika, Fatima El Husseiny, Joël Rousseau and Jacques P. Tremblay
Cells 2026, 15(9), 740; https://doi.org/10.3390/cells15090740 - 22 Apr 2026
Viewed by 242
Abstract
Duchenne muscular dystrophy (DMD) is a fatal X-linked neuromuscular disorder caused by mutations in the dystrophin gene. Prime editing is a versatile genome editing technology capable of introducing precise nucleotide changes without generating double-strand DNA breaks, making it a promising approach for correcting [...] Read more.
Duchenne muscular dystrophy (DMD) is a fatal X-linked neuromuscular disorder caused by mutations in the dystrophin gene. Prime editing is a versatile genome editing technology capable of introducing precise nucleotide changes without generating double-strand DNA breaks, making it a promising approach for correcting pathogenic point mutations. In this study, we applied prime editing to modify mdx-4cv and mdx-5cv mutation-equivalent sites in mouse C2C12 myoblasts in vitro. Initial editing efficiencies were unexpectedly low and were associated with the presence of a 5′-TTCT-3′ motif within engineered prime editing guide RNAs (epegRNAs). epegRNA designs containing this motif exhibited reduced prime editing efficiency, whereas silent substitution eliminating the motif significantly improved editing outcomes, indicating that specific sequence features within epegRNAs can influence editing performance. Rational redesign of epegRNAs to remove this motif substantially enhanced editing efficiency, achieving up to 20% modification at the 4cv target site using an NGG PAM and 21% editing at the 5cv locus using an NGAG PAM. These findings highlight an important sequence-dependent constraint in epegRNA design and provide practical guidance for optimizing prime editing strategies targeting Dmd mutations in vitro. Full article
(This article belongs to the Special Issue Gene Editing Therapies for Hereditary Diseases)
Show Figures

Graphical abstract

Back to TopTop